Editorial

Research Digest

Evidence-forward roundups and evidence maps — what the science actually shows across the peptide landscape, kept honest about the gap between hype and data.

Metabolic

The State of GLP-1 & Incretin Research in 2026

A 2026 evidence roundup of GLP-1, GIP and dual/triple incretin agonists: approved uses, the trial landscape, what is next, and the honest gap between prescription medicine and the unapproved research-peptide market.

Read

Recovery

BPC-157: What the Evidence Actually Shows

BPC-157 has a large and consistent animal literature but almost no published human trial data. This review separates what is genuinely known from what remains unproven, and explains why the online enthusiasm outruns the evidence.

Read

Regulation

Peptide Regulation in 2026: What Changed

2026 reshaped the peptide landscape: the FDA moved to close the GLP-1 compounding window, left popular "research" peptides like BPC-157 and TB-500 in legal limbo pending advisory review, while the EMA fought falsified pens and WADA tightened its doping bans. Here is what actually changed.

Read

Longevity

Longevity Peptides: An Evidence Map

A structured, citation-grounded review of the peptides most associated with longevity — what each one is, where the evidence is genuinely strong, where it is only preclinical, and where marketing has raced ahead of the science.

Read

Growth hormone

Growth Hormone Peptides: A Secretagogue Evidence Roundup

Growth hormone secretagogues coax the pituitary into releasing its own GH. This roundup separates the two mechanistic families, flags which molecules have genuine clinical histories, and is honest about the thin evidence behind performance and anti-aging claims.

Read

Cosmetic

Do Cosmetic Peptides Actually Work? The Science

Topical cosmetic peptides show real but modest effects in controlled trials, and the central scientific challenge — getting an intact peptide through the skin barrier — separates genuine data from marketing.

Read

Quality

Research Peptide Quality & Contamination in 2026

The research-peptide market is largely unregulated, and independent testing repeatedly finds purity, dosing and contamination far outside label claims. This guide explains what quality means analytically and how buyers can assess it.

Read

Cognitive

Nootropic Peptides: Semax, Selank & the Evidence

Semax, Selank, cerebrolysin and dihexa are the peptides most often marketed as "nootropics." The mechanistic science is genuinely interesting, but the human evidence is thin, mostly regional, and rarely replicated to Western standards.

Read

Peptide Knowledge Hub →Peptide Library →